Journal for ImmunoTherapy of Cancer (Nov 2021)
488 Phase 1 trial of first-in-class anti-CD96 monoclonal antibody inhibitor, GSK6097608, monotherapy and combination with anti–PD-1 monoclonal antibody, dostarlimab, in advanced solid tumors
Abstract
No abstracts available.